If you purchased or acquired securities in Kenvue securities pursuant and/or traceable to the registration statement and related prospectus (collectively, the “Registration Statement”) issued in connection with the Company’s May 2023 initial public offering (the “IPO” or “Offering”) and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at… Continue reading KENVUE SHAREHOLDER ACTION REMINDER: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Kenvue To Contact Him Directly To Discuss Their Options
Category: Newswire
INSPIRED SHAREHOLDER INVESTIGATION REMINDER: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Inspired To Contact Him Directly To Discuss Their Options
If you purchased or acquired securities in Inspired and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). You may also click here for additional information: www.faruqilaw.com/INSE. There is no cost or obligation to you. NEW YORK, Nov. 18, 2023 /PRNewswire/ — Faruqi & Faruqi, LLP, a… Continue reading INSPIRED SHAREHOLDER INVESTIGATION REMINDER: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Inspired To Contact Him Directly To Discuss Their Options
XPEL SHAREHOLDER INVESTIGATION REMINDER: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In XPEL To Contact Him Directly To Discuss Their Options
If you purchased or acquired securities in XPEL and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). You may also click here for additional information: www.faruqilaw.com/XPEL. There is no cost or obligation to you. NEW YORK, Nov. 18, 2023 /PRNewswire/ — Faruqi & Faruqi, LLP, a… Continue reading XPEL SHAREHOLDER INVESTIGATION REMINDER: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In XPEL To Contact Him Directly To Discuss Their Options
BRAINSTORM SHAREHOLDER ACTION REMINDER: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Brainstorm To Contact Him Directly To Discuss Their Options
If you purchased or acquired securities in Brainstorm between August 15, 2022 and September 27, 2023 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). You may also click here for additional information: www.faruqilaw.com/BCLI. There is no cost or obligation to you. NEW… Continue reading BRAINSTORM SHAREHOLDER ACTION REMINDER: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Brainstorm To Contact Him Directly To Discuss Their Options
FMC SHAREHOLDER ACTION REMINDER: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In FMC To Contact Him Directly To Discuss Their Options
If you purchased or acquired securities in FMC between November 2, 2022 and October 30, 2023 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). You may also click here for additional information: www.faruqilaw.com/FMC. There is no cost or obligation to you. NEW… Continue reading FMC SHAREHOLDER ACTION REMINDER: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In FMC To Contact Him Directly To Discuss Their Options
DOCGO SHAREHOLDER ACTION REMINDER: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In DocGo To Contact Him Directly To Discuss Their Options
If you purchased or acquired securities in DocGo between November 8, 2022 and September 17, 2023 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). You may also click here for additional information: www.faruqilaw.com/DCGO. There is no cost or obligation to you. NEW… Continue reading DOCGO SHAREHOLDER ACTION REMINDER: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In DocGo To Contact Him Directly To Discuss Their Options
LI-CYCLE SHAREHOLDER ACTION REMINDER: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Li-Cycle To Contact Him Directly To Discuss Their Options
If you purchased or acquired securities in Li-Cycle between June 14, 2022 and October 23, 2023 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). You may also click here for additional information: www.faruqilaw.com/LICY. There is no cost or obligation to you. NEW… Continue reading LI-CYCLE SHAREHOLDER ACTION REMINDER: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Li-Cycle To Contact Him Directly To Discuss Their Options
OUTLOOK SHAREHOLDER ACTION REMINDER: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Outlook To Contact Him Directly To Discuss Their Options
If you purchased or acquired securities in Outlook between December 29, 2022 and August 29, 2023 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). You may also click here for additional information: www.faruqilaw.com/OTLK. There is no cost or obligation to you. NEW… Continue reading OUTLOOK SHAREHOLDER ACTION REMINDER: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Outlook To Contact Him Directly To Discuss Their Options
New Analyses from Pivotal Phase 3 INDIGO Study Reinforce Vorasidenib’s Potential to Change the Treatment Paradigm for IDH-Mutant Diffuse Glioma
Late-breaking analysis from pivotal INDIGO Phase 3 trial demonstrates vorasidenib led to tumor shrinkage in IDH1/2-mutant diffuse glioma First data from Phase 1 trial show the safety and tolerability of vorasidenib plus KEYTRUDA® (pembrolizumab) in recurrent or progressive enhancing IDH1-mutant diffuse astrocytomas BOSTON, Nov. 18, 2023 /PRNewswire/ — New data from Servier’s clinical development program for vorasidenib… Continue reading New Analyses from Pivotal Phase 3 INDIGO Study Reinforce Vorasidenib’s Potential to Change the Treatment Paradigm for IDH-Mutant Diffuse Glioma
Rotterdam The Hague Airport accelerates sustainable fuel blending
ROTTERDAM, The Netherlands, Nov. 17, 2023 /PRNewswire/ — Yesterday, Shell and Rotterdam The Hague Airport (RTHA) signed a long-term agreement to blend sustainable aviation fuel on all aircraft fuelled at the airport, starting in 2024. On top of the European blending mandate of 6%, the airport will accelerate its efforts by setting itself a minimum… Continue reading Rotterdam The Hague Airport accelerates sustainable fuel blending